Composite western medicine formula for treating gout
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A western medicine and formula technology, applied in the field of western medicine compound formulations for the treatment of gout, can solve the problems of increased harmful heavy metal ions, low treatment effect of reducing uric acid, endangering the health of patients, etc., so as to protect gastric mucosa, promote human body detoxification, and promote cell regeneration. band effect
Inactive Publication Date: 2016-04-06
杜玉茗
View PDF2 Cites 5 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
[0002] In recent years, the number of patients with gout has been increasing. Gout is a disease caused by increased purine biosynthesis and metabolism, excessive uric acid production or poor excretion of uric acid, resulting in elevated uric acid in the blood. recurrent inflammatory diseases caused by bursa, cartilage and other tissues. However, most of the traditional gout drugs only have anti-inflammatory and analgesic effects, and the therapeutic effect on reducing uric acid
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0018] Sucralfate 0.5g per capsule, Diclofenac Sodium 0.2g per capsule, Magnesium Oxide 0.1g per capsule, Benzbromarone 0.3g per capsule, Chitin 1.5g per capsule.
[0019] The preparation method is as follows: separately drying sucralfate, diclofenac sodium, magnesium oxide, benzbromarone and chitin, pulverizing, screening through a 250-mesh sieve, mixing uniformly, sterilizing, and packing into hard capsules.
Embodiment 2
[0021] Sucralfate 0.2g per capsule, Diclofenac Sodium 0.01g per capsule, Magnesium Oxide 0.01g per capsule, Benzbromarone 0.1g per capsule, Chitin 0.2g per capsule.
[0022] The preparation method is as follows: separately drying sucralfate, diclofenac sodium, magnesium oxide, benzbromarone and chitin, pulverizing, screening through a 250-mesh sieve, mixing uniformly, sterilizing, and packing into hard capsules.
Embodiment 3
[0024] Sucralfate 0.3g per capsule, Diclofenac Sodium 0.1g per capsule, Magnesium Oxide 0.05g per capsule, Benzbromarone 0.2g per capsule, Chitin 0.8g per capsule.
[0025] The preparation method is as follows: separately drying sucralfate, diclofenac sodium, magnesium oxide, benzbromarone and chitin, pulverizing, screening through a 250-mesh sieve, mixing uniformly, sterilizing, and packing into hard capsules.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
The invention discloses a composite western medicine formula for treating gout. The composite western medicine is prepared from, by weight per granule, 0.2-0.5 g of sucralfate, 0.01-0.2 g of diclofenac sodium, 0.01-0.1 g of magnesium oxide, 0.1-0.3 g of benzbromarone and 0.2-1.5 g of chitin. According to the composite western medicine formula for treating the gout, the good gout treatment using effect is achieved; the activity of xanthine oxidase can be inhibited by using the benzbromarone, and therefore the concentration of uric acid in human blood is effectively lowered; by using the sucralfate, a layer of a protective film is formed to cover the ulcer surface, the effect of protecting the gastric mucosa is achieved, the using side effects of medicine on patients suffering from gastric ulcer and the like are effectively reduced, and meanwhile the effects of eliminating inflammation and relieving pain are obvious; by using the chitin, the effects of activating cells in a human body, preventing cell aging, promoting a newly-born cell band, adsorbing harmful heavy metal ions in the body, promoting human body detoxifying and the like can be achieved; gout patients can be effectively treated, and use is very convenient.
Description
technical field [0001] The invention belongs to the field of pharmaceutical formulations, in particular to a compound formulation of western medicine for treating gout. Background technique [0002] In recent years, the number of patients with gout has been increasing. Gout is a disease caused by increased purine biosynthesis and metabolism, excessive uric acid production or poor excretion of uric acid, resulting in elevated uric acid in the blood. recurrent inflammatory diseases caused by bursa, cartilage and other tissues. However, most of the traditional gout drugs only have anti-inflammatory and analgesic effects, and the therapeutic effect on reducing uric acid is very low, which leads to patients with gout. At the same time, many drugs for the treatment of gout are more harmful to the gastrointestinal tract of patients, especially for some patients with gastric ulcer, the side effects are more obvious, and because the patients take the drugs for the treatment of gout f...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more